Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma.

General Information

NCT#: NCT03250273
Study ID: J1798
Trial Phase: Phase II

Trial Sponsor: Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center, Syndax Pharmaceuticals
Therapies Used in This Trial: Nivolumab, Entinostat

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search